CSIMarket Company Name, Ticker, Competitors, else..


Hookipa Pharma inc   (HOOK)
Other Ticker:  
 


 

Hookipa Pharma inc

HOOK's Financial Statements and Analysis



Hookipa Pharma inc narrowed second quarter of 2024 net loss per share of $-1.52 compare to net loss per share of $-2.20 recorded in the same quarter a year ago a decrease from $1.10 eps realized in I. Quarter (Mar 31 2024).


second quarter of 2024
Earnings Per Share Revenues
$ -1.52 $  1 Mill
$+0.68     $-1M     -51.85 %



Hookipa Pharma Inc 's Revenue fell by -51.85 % in second quarter of 2024 (Jun 30 2024) year on year, to $1 million and declined by -96.48 % sequentially.


Hookipa Pharma Inc is

More on HOOK's Income Statement



Hookipa Pharma Inc in the second quarter of 2024 recorded net loss of $-19.095 million, an increase from net loss of $-18.016 million in II. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $14.383 million in the previous quarter.

More on HOOK's Growth

Hookipa Pharma Inc Inventories
In Jun 30 2024 company's net cash and cash equivalents decreased by $-16 million, capital expenditures grew by -0.445-89.89%, to $0 millions compare to same quarter a year ago

More on HOOK's Cash flow Statement


Hookipa Pharma inc does not pay out common stock dividend.

In trailing twelve-month period Hookipa Pharma inc payed $ -5.88 cash per share, on a free-cash flow basis .

Book value fell by -14.30 % sequentially to $6.85 per share, -30.41% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 6.85 per share from $ 7.99.

Company repurchased 0.51 million shares or 3.92 % in Jun 30 2024.


• More on HOOK's Dividends

 Market Capitalization (Millions) 46
 Shares Outstanding (Millions) 13
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -58
 Capital Exp. (TTM) (Millions $) -4
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 20




Hookipa Pharma inc does not pay out common stock dividend.

In trailing twelve-month period Hookipa Pharma inc had negative $ -5.88 cash flow per share, on a free-cash flow basis .

Book value fell by -14.30 % sequentially to $6.85 per share, -30.41% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 6.85 per share from $ 7.99.

Company repurchased 0.51 million shares or 3.92 % in Jun 30 2024.


• More on HOOK's Balance Sheets

 Market Capitalization (Millions) 46
 Shares Outstanding (Millions) 13
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -58
 Capital Exp. (TTM) (Millions $) -4
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 20
   


  News about Hookipa Pharma inc Earnings

Hookipa Pharma Inc. Sees Impressive 1052.361% Revenue Growth in Q1 2024 Earnings Report

Hookipa Pharma Inc, a biopharmaceutical company specializing in immunotherapeutics, has faced a significant decrease in its stock value over the past year. It went down by a staggering 56.99% from both a year ago and a year before. However, there is hope for the company as its stock is currently trading on the NASDAQ at 5.1% above its 52-week average.
Despite its stock performance, Hookipa Pharma Inc recently published its financial results and business highlights for the fourth quarter and full year of 2023. One of the most notable achievements is the unveiling of the final pivotal design of its Phase 2/3 trial. This trial aims to investigate the efficacy and safety of HB-200 in combination with pembrol...

Hookipa Pharma Inc Faces Setback as Fourth Quarter Revenue Dips Slightly

Hookipa Pharma Inc, a biopharmaceutical company that specializes in immunotherapeutics, has seen a drop in its shares over the course of March. The share price has decreased by -5.97% during this period, bringing it to a total decrease of 10.89% in the past 90 days. Currently, Hookipa Pharma Inc shares are trading on the NASDAQ at -6.8% below its 52 week average.
For the financial fourth quarter of 2023, Hookipa Pharma Inc experienced losses of $-0.16 per share, compared to $-0.11 per share the previous year. However, there was an improvement in earnings per share (EPS), which increased from $-0.17 per share in the prior reporting period. Revenue also saw a decline of -5.378% to $7.41 million, compared t...

Groundbreaking Insights Unveiled: Hookipa Pharma Inc Surpasses Expectations in Fiscal Year Ending September 30, 2023



Hookipa Pharma Inc, a biotechnology company, recently released its financial results for the third quarter of 2023. The results indicate a significant improvement in earnings per share (EPS) and a substantial increase in revenue. However, amidst the positive trends, the company continues to face a net deficit and challenges in accounts receivable management. This article will examine the implications of these financial results and provide insights into how they may impact the future of Hookipa Pharma Inc.
Positive Earnings Per Share (EPS) Improvement:
Hookipa Pharma Inc achieved a noteworthy reduction in losses per share, reporting a decrease from $-0.25 in the previous year to $-0.17 in th...

Investor Interest Surges as Hookipa Pharma Inc's Q2 2023 Report Shows Positive Growth Potential



In ...

Despite a Surge in Revenue, Hookipa Pharma Inc Struggles to Achieve Profitability in Q1 2023

In a recent financial report, Hookipa Pharma Inc has recorded a substantial net loss of $-67 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on investment (ROI) of -59.93%. The company's ROI overall ranking has improved from 4339 in the fourth quarter of 2022 to 2801 in the first quarter of 2023. However, within the Healthcare sector, Hookipa Pharma Inc is lagging behind with 423 other companies having a higher ROI.
Despite the negative financial performance, the company has announced a robust revenue growth of 119.792% on a year-on-year basis, reaching $3.18 million in t...


Date modified: 2024-09-06T20:34:11+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com